VYNE Therapeutics (VYNE) Cash from Financing Activities (2017 - 2026)
VYNE Therapeutics (VYNE) posted Cash from Financing Activities of -$15000.0 for Q1 2026, up 55.88% on a QoQ basis from -$34000.0 in Q2 2025, and up 82.76% year-over-year from -$8207.5 in Q1 2025.
VYNE Therapeutics (VYNE) Cash from Financing Activities (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$15000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 82.76% year-over-year to -$15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268000.0 (down 20.18% YoY) and the FY2025 annual result came in at -$143000.0, down 1.42% from the prior year.
- Cash from Financing Activities was -$15000.0 for Q1 2026 at VYNE Therapeutics, up from -$34000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $82.7 million in Q4 2023 and bottomed at -$217000.0 in Q1 2023.
- A 5-year average of $5.6 million and a median of -$15000.0 in 2026 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 39641.83% — and 2025, when it plunged 1640.0%.
- VYNE Therapeutics' Cash from Financing Activities stood at $208000.0 in 2022, then soared by 39641.83% to $82.7 million in 2023, then plunged by 100.16% to -$132000.0 in 2024, then soared by 74.24% to -$34000.0 in 2025, then jumped by 55.88% to -$15000.0 in 2026.
- Business Quant data shows VYNE's Cash from Financing Activities at -$15000.0 in Q1 2026, -$34000.0 in Q2 2025, and -$87000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | 82.66 Mn |
| Dec 31, 2023 | 82.66 Mn |
| Sep 30, 2023 | -47,000.00 |
| Sep 30, 2023 | -47,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |